Is Monopar Therapeutics Stock a Good Investment?
Monopar Therapeutics Investment Advice | MNPR |
- Examine Monopar Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Monopar Therapeutics' leadership team and their track record. Good management can help Monopar Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Monopar Therapeutics' business and its evolving consumer preferences.
- Compare Monopar Therapeutics' performance and market position to its competitors. Analyze how Monopar Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Monopar Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Monopar Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Monopar Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Monopar Therapeutics is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Insignificant | Details | |
Volatility | Very risky | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Actively responds to the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Monopar Therapeutics Stock
Researching Monopar Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 53.0% of the company outstanding shares are owned by corporate insiders. The book value of Monopar Therapeutics was now reported as 1.73. The company recorded a loss per share of 2.3. Monopar Therapeutics had not issued any dividends in recent years. The entity had 1:5 split on the 13th of August 2024.
To determine if Monopar Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Monopar Therapeutics' research are outlined below:
| Monopar Therapeutics had very high historical volatility over the last 90 days | |
| Monopar Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (8.4 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Monopar Therapeutics currently holds about 16.46 M in cash with (7.86 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.29. | |
| Monopar Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 53.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from seekingalpha.com: Monopar stock rallies 60 percent on Phase 1 data for MNPR-101-Zr |
Monopar Therapeutics Quarterly Cash And Short Term Investments |
|
Monopar Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Monopar Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Monopar Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 28th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Monopar Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Monopar Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-05-09 | 2024-03-31 | -0.12 | -0.1 | 0.02 | 16 | ||
2023-08-10 | 2023-06-30 | -0.18 | -0.16 | 0.02 | 11 | ||
2022-03-24 | 2021-12-31 | -0.19 | -0.21 | -0.02 | 10 | ||
2021-08-12 | 2021-06-30 | -0.19 | -0.17 | 0.02 | 10 | ||
2024-03-28 | 2023-12-31 | -0.15 | -0.12 | 0.03 | 20 | ||
2023-11-09 | 2023-09-30 | -0.17 | -0.14 | 0.03 | 17 | ||
2023-05-11 | 2023-03-31 | -0.22 | -0.19 | 0.03 | 13 | ||
2023-03-23 | 2022-12-31 | -0.2 | -0.23 | -0.03 | 15 |
Monopar Therapeutics Target Price Consensus
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Monopar target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Monopar Therapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 3 | Strong Buy |
Most Monopar analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Monopar stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Monopar Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationMonopar Therapeutics Target Price Projection
Monopar Therapeutics' current and average target prices are 4.31 and 8.50, respectively. The current price of Monopar Therapeutics is the price at which Monopar Therapeutics is currently trading. On the other hand, Monopar Therapeutics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Monopar Therapeutics Market Quote on 20th of September 2024
Target Price
Analyst Consensus On Monopar Therapeutics Target Price
Monopar Therapeutics Analyst Ratings
Monopar Therapeutics' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Monopar Therapeutics stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Monopar Therapeutics' financials, market performance, and future outlook by experienced professionals. Monopar Therapeutics' historical ratings below, therefore, can serve as a valuable tool for investors.Know Monopar Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Monopar Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Monopar Therapeutics backward and forwards among themselves. Monopar Therapeutics' institutional investor refers to the entity that pools money to purchase Monopar Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Fmr Inc | 2024-06-30 | 0.0 | Ubs Group Ag | 2024-06-30 | 0.0 | Renaissance Technologies Corp | 2024-03-31 | 0.0 | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 0.0 | Two Sigma Investments Llc | 2024-03-31 | 0.0 | Hrt Financial Llc | 2024-06-30 | 0.0 | Millennium Management Llc | 2024-03-31 | 192.4 K | Vanguard Group Inc | 2024-03-31 | 45.2 K | Geode Capital Management, Llc | 2024-03-31 | 41.2 K | Gerber Llc | 2024-06-30 | 28 K | Virtu Financial Llc | 2024-03-31 | 23.8 K |
Monopar Therapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 15.84 M.Market Cap |
|
Monopar Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.14) | (1.20) | |
| Return On Capital Employed | (1.58) | (1.66) | |
| Return On Assets | (1.14) | (1.20) | |
| Return On Equity | (1.50) | (1.58) |
Determining Monopar Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Monopar Therapeutics is a good buy. For example, gross profit margin measures Monopar Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Monopar Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Monopar Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Monopar Therapeutics. Check Monopar Therapeutics' Beneish M Score to see the likelihood of Monopar Therapeutics' management manipulating its earnings.
Evaluate Monopar Therapeutics' management efficiency
Monopar Therapeutics has return on total asset (ROA) of (0.5345) % which means that it has lost $0.5345 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0231) %, meaning that it created substantial loss on money invested by shareholders. Monopar Therapeutics' management efficiency ratios could be used to measure how well Monopar Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 09/20/2024, Return On Tangible Assets is likely to drop to -1.2. In addition to that, Return On Capital Employed is likely to drop to -1.66. At this time, Monopar Therapeutics' Total Assets are relatively stable compared to the past year. As of 09/20/2024, Total Current Assets is likely to grow to about 11.2 M, while Non Current Assets Total are likely to drop slightly above 12 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.02 | 2.12 | |
| Tangible Book Value Per Share | 2.02 | 2.12 | |
| Enterprise Value Over EBITDA | 0.29 | 0.31 | |
| Price Book Value Ratio | 0.84 | 0.80 | |
| Enterprise Value Multiple | 0.29 | 0.31 | |
| Price Fair Value | 0.84 | 0.80 | |
| Enterprise Value | 163.9 M | 235 M |
The analysis of Monopar Therapeutics' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Monopar Therapeutics' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Monopar Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta 1.162 |
Basic technical analysis of Monopar Stock
As of the 20th of September, Monopar Therapeutics secures the Risk Adjusted Performance of 0.0475, downside deviation of 6.71, and Mean Deviation of 5.06. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Monopar Therapeutics, as well as the relationship between them. Please verify Monopar Therapeutics standard deviation, value at risk, as well as the relationship between the Value At Risk and kurtosis to decide if Monopar Therapeutics is priced some-what accurately, providing market reflects its recent price of 4.31 per share. Given that Monopar Therapeutics has jensen alpha of 0.2334, we recommend you to check Monopar Therapeutics's last-minute market performance to make sure the company can sustain itself at a future point.Monopar Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Monopar Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Monopar Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Monopar Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Monopar Therapeutics' Outstanding Corporate Bonds
Monopar Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Monopar Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Monopar bonds can be classified according to their maturity, which is the date when Monopar Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US610202BR34 Corp BondUS610202BR34 | View | |
| US610202BP77 Corp BondUS610202BP77 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View |
Understand Monopar Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Monopar Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0475 | |||
| Market Risk Adjusted Performance | 0.2431 | |||
| Mean Deviation | 5.06 | |||
| Semi Deviation | 6.18 | |||
| Downside Deviation | 6.71 | |||
| Coefficient Of Variation | 2110.35 | |||
| Standard Deviation | 9.95 | |||
| Variance | 98.94 | |||
| Information Ratio | 0.0348 | |||
| Jensen Alpha | 0.2334 | |||
| Total Risk Alpha | (0.95) | |||
| Sortino Ratio | 0.0516 | |||
| Treynor Ratio | 0.2331 | |||
| Maximum Drawdown | 69.87 | |||
| Value At Risk | (9.02) | |||
| Potential Upside | 9.76 | |||
| Downside Variance | 44.96 | |||
| Semi Variance | 38.24 | |||
| Expected Short fall | (6.03) | |||
| Skewness | 4.05 | |||
| Kurtosis | 26.77 |
| Risk Adjusted Performance | 0.0475 | |||
| Market Risk Adjusted Performance | 0.2431 | |||
| Mean Deviation | 5.06 | |||
| Semi Deviation | 6.18 | |||
| Downside Deviation | 6.71 | |||
| Coefficient Of Variation | 2110.35 | |||
| Standard Deviation | 9.95 | |||
| Variance | 98.94 | |||
| Information Ratio | 0.0348 | |||
| Jensen Alpha | 0.2334 | |||
| Total Risk Alpha | (0.95) | |||
| Sortino Ratio | 0.0516 | |||
| Treynor Ratio | 0.2331 | |||
| Maximum Drawdown | 69.87 | |||
| Value At Risk | (9.02) | |||
| Potential Upside | 9.76 | |||
| Downside Variance | 44.96 | |||
| Semi Variance | 38.24 | |||
| Expected Short fall | (6.03) | |||
| Skewness | 4.05 | |||
| Kurtosis | 26.77 |
Consider Monopar Therapeutics' intraday indicators
Monopar Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Monopar Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Daily Balance Of Power | (9,223,372,036,855) | |||
| Rate Of Daily Change | 0.96 | |||
| Day Median Price | 4.31 | |||
| Day Typical Price | 4.31 | |||
| Price Action Indicator | (0.1) | |||
| Period Momentum Indicator | (0.19) |
Monopar Therapeutics Corporate Filings
8K | 12th of September 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 22nd of July 2024 Other Reports | ViewVerify | |
| 11th of July 2024 Other Reports | ViewVerify | |
F3 | 3rd of July 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Monopar Stock media impact
Far too much social signal, news, headlines, and media speculation about Monopar Therapeutics that are available to investors today. That information is available publicly through Monopar media outlets and privately through word of mouth or via Monopar internal channels. However, regardless of the origin, that massive amount of Monopar data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Monopar Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Monopar Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Monopar Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Monopar Therapeutics alpha.
Monopar Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Monopar Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Monopar Therapeutics Corporate Executives
Elected by the shareholders, the Monopar Therapeutics' board of directors comprises two types of representatives: Monopar Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Monopar. The board's role is to monitor Monopar Therapeutics' management team and ensure that shareholders' interests are well served. Monopar Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Monopar Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christopher Starr | CoFounder Board | Profile | |
| Kim CPA | Secretary, CFO | Profile | |
| Karthik CFA | Principal CFO | Profile |
Additional Tools for Monopar Stock Analysis
When running Monopar Therapeutics' price analysis, check to measure Monopar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Monopar Therapeutics is operating at the current time. Most of Monopar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Monopar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Monopar Therapeutics' price. Additionally, you may evaluate how the addition of Monopar Therapeutics to your portfolios can decrease your overall portfolio volatility.